JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $72

TG Therapeutics, Inc.

TG Therapeutics, Inc.

TGTX

0.00

JP Morgan analyst Brian Cheng maintains TG Therapeutics (NASDAQ: TGTX) with a Overweight and raises the price target from $65 to $72.